Background-The effect of prearrest left ventricular ejection fraction (LVEF) on outcome after cardiac arrest is unknown. Methods and Results-During a 26-month period, Utstein-style data were prospectively collected on 800 consecutive inpatient adult index cardiac arrests in an observational, single-center study at a tertiary cardiac care hospital. Prearrest echocardiograms were performed on 613 patients (77%) at 11Ϯ14 days before the cardiac arrest. Outcomes among patients with normal or nearly normal prearrest LVEF (Ն45%) were compared with those of patients with moderate or severe dysfunction (LVEF Ͻ45%) by 2 and logistic regression analyses. Survival to discharge was 19% in patients with normal or nearly normal LVEF compared with 8% in those with moderate or severe dysfunction (adjusted odds ratio, 4.8; 95% confidence interval, 2.3 to 9.9; PϽ0.001) but did not differ with regard to sustained return of spontaneous circulation (59% versus 56%; Pϭ0.468) or 24-hour survival (39% versus 36%; Pϭ0.550). Postarrest echocardiograms were performed on 84 patients within 72 hours after the index cardiac arrest; the LVEF decreased 25% in those with normal or nearly normal prearrest LVEF (60Ϯ9% to 45Ϯ14%; PϽ0.001) and decreased 26% in those with moderate or severe dysfunction (31Ϯ7% to 23Ϯ6%, PϽ0.001). For all patients, prearrest -blocker treatment was associated with higher survival to discharge (33% versus 8%; adjusted odds ratio, 3.9; 95% confidence interval, 1.8 to 8.2; PϽ0.001). Conclusions-Moderate and severe prearrest left ventricular systolic dysfunction was associated with substantially lower rates of survival to hospital discharge compared with normal or nearly normal function.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.